ERBB2 and triple-negative breast carcinoma: This approach has become increasingly pertinent due to the growing use of NACT, which, although initially reserved for locally advanced breast cancers (LABCs) [3], is now recommended as the preferred treatment for HER2-positive (HER2 +) and triple-negative breast cancer (TNBC) [25], [26], even in early-stage cases where tumors are larger than 1.5 cm, as per guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN).